Victory For Takeda Abbott In Prostate Drug Patent Suit
QLT said it plans to appeal the jury verdict.
TAP, a joint venture between Takeda Chemical Industries and Abbot Laboratories, filed the suit in 2003, alleging that the Eligard prostate cancer treatment controlled by all three defendants infringes a TAP patent.
Eligard was developed by Atrix Laboratories, which was purchased by QLT in November...
To view the full article, register now.